NEUROTOXIN COMPOSITIONS FOR USE IN TREATING CARDIOVASCULAR DISORDERS

1 )- 38 ) (canceled)

39 ) A method of treating a cardiovascular disorder comprising:

administering a botulinum toxin into the stellate ganglion nerve of a mammal or the vicinity thereof to treat at least one of angina, arrhythmias of heart rate, a myocardial contractility disorder, coronary artery disease, and high blood pressure;

thereby reducing the occurrence of at least one symptom of the disorder.

40 ) The method of claim 39 , wherein the botulinum toxin is native immunotype A.

41 ) The method of claim 40 , wherein the botulinum toxin is administered by injection.

42 ) A method of treating a cardiovascular disorder comprising;

administering a botulinum toxin into the stellate ganglion or the vicinity thereof in a subject with a cardiovascular disorder to thereby treat their symptoms.

43 ) A method of treating a cardiovascular disorder comprising administering a botulinum toxin into the stellate ganglion or the vicinity thereof wherein the administration is performed by imaging the treatment area.

44 ) The method of claim 39 or 42 - 43 , wherein the botulinum toxin is a botulinum toxin type A, B, C, E, or F.

45 ) The method of claim 44 , wherein the total dose of the botulinum toxin is 50-100 Units.

46 ) The method of claim 44 , wherein the total dose of the botulinum toxin is 25-120 Units.

47 ) The method of claim 44 , wherein the total dose of the botulinum toxin is 40-120 Units.

48 ) The method of claim 45 , wherein said cardiovascular disorder comprises arrhythmias of heart rate.

49 ) The method of claim 45 , wherein said cardiovascular disorder comprises myocardial contractility.

50 ) The method of claim 45 , wherein said cardiovascular disorder comprises a coronary artery disease.

51 ) The method of claim 45 , wherein said cardiovascular disorder comprises high blood pressure.

52 ) A method for comparing the efficacy and safety of two different Botulinum toxins, comprising:

measuring a reduction of a cardiovascular disorder symptom of an individual resulting from administration of a first botulinum neurotoxin; measuring a reduction of a cardio disorder symptom of an individual resulting from administration of a second botulinum neurotoxin; and comparing the reduction in symptoms to determine a difference between the first botulinum neurotoxin and the second botulinum neurotoxin.

53 ) A method of treating a cardiovascular disorder comprising the steps of administering a botulinum toxin into the stellate ganglion nerve of a mammal or into the vicinity thereof to treat at least one of arrhythmias of heart rate, a myocardial contractility disorder, coronary artery disease, and high blood pressure; and administering a local anesthetic to the stellate ganglion nerve of said mammal, thereby reducing the occurrence of at least one symptom of the disorder.

54 ) The method of claim 53 , wherein said local anesthetic comprises lidocaine.

55 ) The method of claim 53 , wherein said botulinum toxin is type A, B, C, E or F.

56 ) The method of claim 1 , wherein said administration comprises locating the cricoid cartilage of the larynx to identify the location of the stellate ganglion and injecting into the stellate ganglion or vicinity thereof.

57 ) The method of claim 43 , wherein said imaging comprises fluoroscopy.

58 ) The method of claim 43 , wherein said imaging comprises ultrasound.

59 ) The method of claim 57 , wherein said treating arrhythmia comprises one of stabilizing ventricular rhythm or reducing tachycardia symptoms.

61 ) The method of claim 55 , wherein the total dose of the botulinum toxin is 50-100 Units.

62 ) The method of claim 55 , wherein the total dose of the botulinum toxin is 25-120 Units.

63 ) The method of claim 55 , wherein the total dose of the botulinum toxin is 40-110 Units.

64 ) The method of claim 55 , wherein said cardiovascular disorder comprises arrhythmias of heart rate.

65 ) The method of claim 55 , wherein said cardiovascular disorder comprises myocardial contractility.

66 ) The method of claim 55 , wherein said cardiovascular disorder comprises a coronary artery disease.

67 ) The method of claim 55 , wherein said cardiovascular disorder comprises high blood pressure.

68 ) The method of claim 55 , wherein said cardiovascular disorder comprises angina.